Recombinant Human FGF R1α (IIIc)

Recombinant Human FGF R1α (IIIc) is used in research applications to study and manipulate FGF signaling pathways that regulate key biological processes such as cellular proliferation, differentiation, migration, morphogenesis, and tissue patterning. This receptor isoform is particularly relevant for investigations involving mesenchymal tissues, cancer biology, and developmental biology due to its distinct ligand-binding properties and tissue-specific expression.

Key scientific reasons to use Recombinant Human FGF R1α (IIIc):

• Functional Assays: Recombinant FGFR1α (IIIc) is validated for use in functional assays, enabling precise analysis of FGF ligand-receptor interactions and downstream signaling events.
• Isoform-Specific Signaling: The IIIc splice variant of FGFR1α has unique binding affinities for FGF ligands compared to other isoforms, allowing researchers to dissect isoform-specific signaling mechanisms and their biological consequences.
• Disease Modeling: FGFR1α (IIIc) is upregulated in various diseases, including breast and pancreatic cancers, Pfeiffer syndrome, and osteoarthritis. Recombinant protein enables in vitro and in vivo modeling of these conditions and evaluation of therapeutic strategies targeting FGFR1α (IIIc).
• Anti-Angiogenic and Anti-Proliferative Studies: Soluble FGFR1α (IIIc) has demonstrated anti-angiogenic and anti-proliferative effects in cancer cell models, making it valuable for cancer research and drug development.
• High Purity and Consistency: Recombinant proteins offer superior purity, bioactivity, and batch-to-batch consistency compared to native proteins, which is critical for reproducible experimental results.
• Organoid and Tissue Engineering: Recombinant growth factors, including FGFR1α (IIIc), are essential for organoid culture and tissue engineering applications, supporting the study of complex tissue-specific signaling and development.

Best practices for using recombinant FGFR1α (IIIc) include:

• Employing it in controlled functional assays to study FGF signaling.
• Using it as a soluble decoy receptor to inhibit endogenous FGF signaling in disease models.
• Combining it with specific FGF ligands to investigate receptor-ligand specificity and downstream effects.

In summary, Recombinant Human FGF R1α (IIIc) is a powerful tool for dissecting FGF signaling, modeling disease, and developing therapeutic strategies, with advantages in purity, specificity, and reproducibility for advanced research applications.

You should not use recombinant human FGF R1α (IIIc) as a standard for quantification or calibration in ELISA assays designed to measure FGF ligands (such as FGF1 or FGF2); ELISA standards must match the analyte being quantified.

Key points:

• ELISA standards must be the same molecule as the analyte: Quantitative ELISA assays require a standard curve generated using a purified form of the same protein you wish to measure in your samples. For example, to quantify FGF1, you must use recombinant or purified FGF1 as the standard. Using a different protein, even if related (such as a receptor or a different isoform), will not yield accurate or meaningful results.

• FGF R1α (IIIc) is a receptor, not a ligand: FGF R1α (IIIc) is a splice variant of the fibroblast growth factor receptor 1, not an FGF ligand. ELISA kits for FGF1 or FGF2 are calibrated with recombinant FGF1 or FGF2, not with their receptors. The receptor and ligand have different structures and epitopes, so antibodies in FGF ligand ELISAs will not recognize the receptor as a standard.

• Cross-reactivity and interference: Some ELISA kits specifically test for cross-reactivity and interference from related proteins, including FGF receptors, and report no cross-reactivity or interference at relevant concentrations. This further confirms that FGF R1α (IIIc) is not suitable as a standard for FGF ligand quantification.

• Best practice: Always use the exact recombinant protein (same isoform and species) as your standard for calibration in ELISA assays. If you are quantifying FGF R1α (IIIc) itself, you would need an ELISA specifically designed for that receptor, using the same recombinant receptor as the standard.

In summary:
Recombinant human FGF R1α (IIIc) cannot be used as a standard for quantifying FGF ligands in ELISA assays. Use only the exact recombinant ligand (e.g., FGF1, FGF2) as the standard for those assays. If you need to quantify FGF R1α (IIIc), use an assay specifically validated for that receptor, with the corresponding standard.

Recombinant Human FGF R1α (IIIc) has been validated in published research primarily for applications involving cell signaling studies, receptor-ligand interaction assays, and functional cell-based assays. Specifically, it is used to investigate the biological activity and specificity of FGF receptor isoforms, their role in cell proliferation, and their interactions with fibroblast growth factors.

Key validated applications include:

• Cell-based functional assays: Recombinant FGF R1α (IIIc) is used to study its ability to bind FGF ligands and modulate cellular responses such as proliferation and differentiation, particularly in fibroblast and epithelial cell models. These assays help elucidate the receptor’s role in FGF signaling pathways.

• Receptor-ligand binding studies: The protein is employed in biochemical assays to characterize the specificity and affinity of FGF R1α (IIIc) for various FGF family members, distinguishing its activity from other FGFR isoforms.

• Immunoassays and interference studies: Recombinant FGF R1α (IIIc) has been tested for interference in multiplex immunoassays, such as Luminex-based assays, to ensure specificity when quantifying FGF ligands or related proteins in biological samples.

• Protein interaction mapping: It is used as a probe in studies aiming to identify direct cellular interaction partners and downstream signaling components, often in the context of genome-scale pathway identification.

• Cell culture supplementation: The recombinant receptor is sometimes used to modulate cell growth and differentiation in vitro, particularly in immunology and oncology research settings.

Additional notes:

• Published protocols emphasize the importance of using lot-specific datasheets and maintaining protein integrity for reproducible results in cell culture and biochemical assays.
• While FGF R1α (IIIc) is closely related to other FGFR isoforms, its unique ligand-binding properties make it a valuable tool for dissecting isoform-specific signaling mechanisms.

If you require details on a specific assay type (e.g., ELISA, Western blot, flow cytometry), please specify, as most published validations focus on functional and binding assays rather than direct detection of the recombinant receptor itself.

To reconstitute and prepare Recombinant Human FGF R1α (IIIc) protein for cell culture experiments, first centrifuge the vial briefly to collect the lyophilized powder at the bottom. Reconstitute the protein aseptically in sterile buffer—since the protein is lyophilized from modified Dulbecco’s phosphate buffered saline (PBS) pH 7.2–7.3, it is recommended to use sterile PBS (without calcium or magnesium) for reconstitution.

Step-by-step protocol:

• Centrifuge the vial briefly (10–30 seconds) to ensure all powder is at the bottom.
• Add sterile PBS (pH 7.2–7.3, without calcium or magnesium) to achieve your desired stock concentration, typically between 0.1–1.0 mg/mL.
• Gently mix the solution by pipetting up and down or gentle vortexing. Avoid vigorous agitation to prevent protein denaturation.
• Allow the protein to dissolve completely (usually 5–10 minutes at room temperature or 4°C).
• Aliquot the stock solution to minimize freeze-thaw cycles.
• Storage: After reconstitution, store aliquots at 2–8°C for up to one month, or at –20°C to –70°C for longer-term storage. Avoid repeated freeze-thaw cycles.

Additional recommendations:

• For cell culture applications, further dilute the stock in culture medium or buffer containing a carrier protein such as 0.1% bovine serum albumin (BSA) to stabilize the protein and prevent adsorption to plasticware.
• Confirm the absence of endotoxin if sensitive cell types are used; the referenced product has <0.01 EU/µg endotoxin.
• Always consult the product-specific Certificate of Analysis or datasheet for any lot-specific instructions.

Summary Table

This protocol ensures optimal solubility, stability, and bioactivity of Recombinant Human FGF R1α (IIIc) for cell culture experiments.